AI Article Synopsis
- Biliary tract cancer (BTC) has poor prognosis and is commonly treated palliatively with gemcitabine and cisplatin since the ABC-02 trial in 2010, which set the standard of care.
- This study evaluated the effectiveness and safety of this treatment approach in real-world patients, comparing those who met the ABC-02 trial criteria to those who did not, along with a group receiving supportive care.
- Results showed that both chemotherapy groups had similar overall and progression-free survival rates, indicating that gemcitabine and cisplatin are effective for a broader range of BTC patients than previously recognized.
Article Abstract
Background: Biliary tract cancer (BTC) is an uncommon cancer with an unfavorable prognosis. Since 2010, the standard of care for patients with unresectable BTC is palliative treatment with gemcitabine plus cisplatin, based on the landmark phase III ABC-02 trial. This current study aims to evaluate the efficacy and safety of gemcitabine and cisplatin in patients with unresectable cholangiocarcinoma and gallbladder cancer in daily practice that meet the criteria for the ABC-02 trial in comparison to patients who did not.
Methods: Patients diagnosed with unresectable BTC between 2010 and 2015 with an indication for gemcitabine and cisplatin were included. We divided these patients into three groups: (I) patients who received chemotherapy and met the criteria of the ABC-02 trial, (II) patients who received chemotherapy and did not meet these criteria and (III) patients who had an indication for chemotherapy, but received best supportive care without chemotherapy. Primary outcome was overall survival (OS) and secondary outcome was progression-free survival (PFS).
Results: We collected data of 208 patients, of which 138 (66.3%) patients received first line chemotherapy with gemcitabine and cisplatin. Median OS of 69 patients in group I, 63 patients in group II and 65 patients in group III was 9.6 months (95%CI = 6.7-12.5), 9.5 months (95%CI = 7.7-11.3) and 7.6 months (95%CI = 5.0-10.2), respectively. Median PFS was 6.0 months (95%CI = 4.4-7.6) in group I and 5.1 months (95%CI = 3.7-6.5) in group II. Toxicity and number of dose reductions (p = .974) were comparable between the two chemotherapy groups.
Conclusion: First-line gemcitabine and cisplatin is an effective and safe treatment for patients with unresectable BTC who do not meet the eligibility criteria for the ABC-02 trial. Median OS, PFS and treatment side effects were comparable between the patients who received chemotherapy (group I vs. group II).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/0284186X.2017.1418532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synergistic Interactions Between Probiotics and Anticancer Drugs: Mechanisms, Benefits, and Challenges.
Probiotics Antimicrob Proteins
January 2025
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Research into the role of probiotics-often referred to as "living supplements"-in cancer therapy is still in its early stages, and uncertainties regarding their effectiveness remain. Relevantly, chemopreventive and therapeutic effects of probiotics have been determined. There is also substantial evidence supporting their potential in cancer treatment such as immunotherapy.
View Article and Find Full Text PDFCase report: A rare case of delayed drug-induced hyponatremia in recurrent upper tract urothelial carcinoma following GC and Tislelizumab treatment.
Front Oncol
January 2025
The Oncology Department, Shanxi Hospital of Traditional Chinese Medicine, Taiyuan, China.
Drug-induced hyponatremia is an adverse reaction with accelerated electrolyte disturbance. This study reported a rare case of delayed hyponatremia in a 68year-old female with recurrent upper tract urothelial carcinoma after Gemcitabine plus Cisplatin (GC) and Tislelizumab treatment. She had left ureter surgery, recurrence a year later with mildly abnormal kidney function (glomerular filtration rate (GFR) was 54.
View Article and Find Full Text PDFInitial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center.
Cancers (Basel)
January 2025
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Biliary tract cancers (BTCs), including gallbladder and bile duct cancers, have a poor prognosis. Recent advances in chemotherapy, such as using targeted drugs for specific gene mutations, have improved outcomes. Gemcitabine plus cisplatin chemotherapy has been the standard of care for the primary treatment of BTCs, but secondary treatment had not been established until recently.
View Article and Find Full Text PDFTreatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study.
Cancers (Basel)
January 2025
Division of Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.
Historically, the standard of care for advanced biliary tract cancers (aBTCs) was gemcitabine plus cisplatin (GemCis). Immunotherapy plus GemCis is now recommended as a first-line treatment for aBTCs. Whether patients can tolerate eight cycles of GemCis in clinical practice, as per the Advanced Biliary Cancer (ABC)-02 study, remains to be assessed.
View Article and Find Full Text PDFThe Immune-Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies.
Cancers (Basel)
January 2025
Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy.
Cholangiocarcinoma (CCA) represents approximately 3% of all gastrointestinal cancers and is a highly heterogeneous and aggressive malignancy originating from the epithelial cells of the biliary tree. CCA is classified by anatomical location into intrahepatic (iCCA), extrahepatic (eCCA), gallbladder cancer (GBC), and ampullary cancers. Although considered a rare tumor, CCA incidence has risen globally, particularly due to the increased diagnosis of iCCA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!